HomeAI · summaries
Storia in 3 fonti
Amgen and the FDA want two different outcomes for Tavneos. What will patients do?
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
FDA hearing on Amgen's Tavneos will include findings from an independent review
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare…
- ·
benzinga.com
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Amgen (NASDAQ:AMGN)
Amgen challenges FDA's proposed Tavneos withdrawal, seeks hearing, and cites independent Duke review of trial data.
- ·
endpoints.news
Amgen and the FDA want two different outcomes for Tavneos. What will patients do?
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market.